Literature DB >> 1985713

Prognostic value of histopathology in Ewing's sarcoma. Long-term follow-up of distal extremity primary tumors.

K R Hartman1, T J Triche, T J Kinsella, J S Miser.   

Abstract

The pathologic material from 56 patients diagnosed initially as Ewing's sarcoma of the distal extremity and treated on National Cancer Institute protocols between 1968 and 1984 was reviewed and correlated with clinical outcome. Histologically, the tumors were categorized, based on recent pathologic criteria, into three diagnostic groups: (1) typical Ewing's sarcoma, (2) atypical Ewing's sarcoma, and (3) other (predominantly peripheral neuroepithelioma [PN]). Thirty-two patients (57%) had typical Ewing's, 13 (23%) were atypical, and 11 (20%) were in the "other" diagnostic category (seven [13%] PN, two primitive rhabdomyosarcoma, one primitive sarcoma of bone, and one synovial cell sarcoma). No cases of metastatic neuroblastoma, osteosarcoma, or lymphoma were found. Forty-five patients had localized disease at diagnosis; 11 had metastases. Patients with typical Ewing's sarcoma were less likely to have metastatic disease at the time of diagnosis. Only two of 32 patients with typical Ewing's sarcoma had metastases compared with nine of 24 patients in the two other groups. The pattern of relapse was also different in these other groups compared with typical Ewing's patients; five patients developed lymph node metastases and two patients developed brain metastases. Although the presence of metastatic disease at diagnosis was a strong negative prognostic factor, our histologic grouping was independently prognostic of clinical outcome in patients with localized disease. Patients with typical osseous Ewing's sarcoma had an improved overall survival (P2 = 0.03) and patients with other tumors (neither typical nor atypical Ewing's sarcoma) had a poorer disease-free survival (P2 = 0.02). Since no generally accepted histopathologic prognostic criteria exist for Ewing's sarcoma, the potential value of our proposed classification should be evaluated in a larger retrospective and a prospective study.

Entities:  

Mesh:

Year:  1991        PMID: 1985713     DOI: 10.1002/1097-0142(19910101)67:1<163::aid-cncr2820670128>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  (Sub)periosteal Ewing's sarcoma of bone.

Authors:  P Wuisman; A Roessner; S Blasius; R Erlemann; W Winkelmann; J Ritter
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support.

Authors:  Antonio Llombart-Bosch; Isidro Machado; Samuel Navarro; Franco Bertoni; Patrizia Bacchini; Marco Alberghini; Apollon Karzeladze; Nikita Savelov; Semyon Petrov; Isabel Alvarado-Cabrero; Doina Mihaila; Philippe Terrier; Jose Antonio Lopez-Guerrero; Piero Picci
Journal:  Virchows Arch       Date:  2009-10-17       Impact factor: 4.064

3.  Additional chromosome 1q aberrations and der(16)t(1;16), correlation to the phenotypic expression and clinical behavior of the Ewing family of tumors.

Authors:  B Stark; C Mor; M Jeison; R Gobuzov; I J Cohen; Y Goshen; J Stein; S Fisher; S Ash; I Yaniv; R Zaizov
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

4.  Intracranial peripheral primitive neuroectodermal tumor manifesting as abducens nerve palsy.

Authors:  N Horinaka; Y Ito; M Miyajima; M Hishii; K Suzuki; M Saito; H Arai
Journal:  Childs Nerv Syst       Date:  2005-01-19       Impact factor: 1.475

5.  Classification of histopathologic changes following chemotherapy in Ewing's sarcoma of bone.

Authors:  H J van der Woude; J L Bloem; A H Taminiau; M A Nooy; P C Hogendoorn
Journal:  Skeletal Radiol       Date:  1994-10       Impact factor: 2.199

6.  Comparison of Latino and non-Latino patients with Ewing sarcoma.

Authors:  Jeremy Sharib; Andrew Horvai; Florette K Gray Hazard; Heike Daldrup-Link; Robert Goldsby; Neyssa Marina; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2013-08-23       Impact factor: 3.167

7.  Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches.

Authors:  Kevin Campbell; David Shulman; Katherine A Janeway; Steven G DuBois
Journal:  Sarcoma       Date:  2018-08-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.